Product Description
APR-TD011 is a wound cleansing spray being developed by Applied Pharma Research for the treatment of epidermolysis bullosa. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05533866?term=APR-TD011&draw=2&rank=1)
Mechanisms of Action: Device
Novel Mechanism: No
Modality: Device
Route of Administration: N/A
FDA Designation: Orphan Drug - Phenylketonurias *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Applied Pharma Research
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Epidermolysis Bullosa
Phase 1: Epidermolysis Bullosa, Junctional|T-Cell Cutaneous Lymphoma|T-Cell Peripheral Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| None | P1 |
None |
Epidermolysis Bullosa |
None |
None |
||
| STU00217913 | P1 |
Not yet recruiting |
T-Cell Cutaneous Lymphoma|T-Cell Peripheral Lymphoma |
2026-12-01 |
2024-03-13 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
|
| NCT05533866 | P1 |
Completed |
Epidermolysis Bullosa, Junctional |
2024-09-24 |
2025-04-30 |
Patient Enrollment|Primary Endpoints|Study Completion Date|Treatments|Trial Status |